HilleVax, Inc. (HLVX)
NASDAQ: HLVX · IEX Real-Time Price · USD
12.02
-0.56 (-4.45%)
At close: Apr 25, 2024, 4:00 PM
12.62
+0.60 (4.99%)
After-hours: Apr 25, 2024, 7:01 PM EDT
Company Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.
It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021.
HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
HilleVax, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | Apr 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 90 |
| CEO | Dr. Robert M. Hershberg M.D., Ph.D. |
Contact Details
Address: 321 Harrison Ave, Suite 500 Boston, Massachusetts 02118 United States | |
| Phone | (617) 213-5054 |
| Website | hillevax.com |
Stock Details
| Ticker Symbol | HLVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001888012 |
| CUSIP Number | 43157M102 |
| ISIN Number | US43157M1027 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert M. Hershberg M.D., Ph.D. | President, Chief Executive Officer and Chairman of the Board |
| Dr. Aditya Kohli Ph.D. | Chief Business Officer and Director |
| Shane A. Maltbie | Chief Financial Officer and Treasurer |
| Sean McLoughlin | Chief Operating Officer |
| Dr. Anju Chatterji Ph.D. | Chief Technology Officer |
| Paul S. Bavier J.D. | General Counsel, Secretary and Chief Administrative Officer |
| Astrid Borkowski M.D., Ph.D. | Chief Medical Officer |
| Ozzie Berger | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 20, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 20, 2024 | 144 | Filing |
| Mar 20, 2024 | 10-K | Annual Report |
| Mar 20, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |